This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Paget Disease of the Skull두개골의 파젯병 (두개골의 Paget병)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: M88.0 | Special Copayment Reduction: V213 (rare disease Special Copayment Reduction)
B. SynonymsPaget disease of the skull, osteitis deformans of skull, Paget's disease of skull
C. Adult onsetLikelihood of first onset in adulthood very high (essentially an adult-only disease) — typically diagnosed after age 50, and onset before age 40 is extremely rare. Prevalence is highest from the 70s onward, giving it the character of a disease of older adults.
1. HistoryFirst described by Sir James Paget in 1877 → named "osteitis deformans." Diagnosis established with X-rays in the 1930s. Bisphosphonates became standard treatment in the 1990s. SQSTM1 gene association published in 2003.
2. CausesExcessive activation of osteoclasts and subsequent abnormal bone remodeling. Genetic predisposition (SQSTM1, etc.) + environmental factors (paramyxovirus infection hypothesis). Skull-specific involvement.
3. GeneticsSQSTM1 (p62) gene mutations (autosomal dominant, about 25–40% of familial Paget disease). Bone metabolism–related genes such as TNFRSF11A (RANK), TNFRSF11B (OPG), and CSF1R. VCP variants possible.
4. General epidemiologyAbout 2–3% of people aged 50 or older in the United Kingdom and Australia. Rare in Korea and Asia (less than 1 per 100,000). Male predominance (2:1). Prevalence rises with age. Declining prevalence trend in the West over recent decades.
5. PathophysiologyExcessive bone resorption by overactive osteoclasts → disorganized bone formation (mosaic bone pattern). In the skull, manifests as increased intracranial pressure, compression of the cranial nerve foramina (cranial nerve palsies), and Pagetic skull enlargement.
6. SymptomsHeadache (skull enlargement), progressive hearing loss (involvement of the inner ear bones), skull enlargement (hats become too small), cervical cord compression (with basilar invagination), increased intracranial pressure, cranial nerve palsies. Asymptomatic cases are also common.
7. SignsAsymmetric skull enlargement. Skull X-ray: cotton-wool bone findings, thickening. Marked ALP (alkaline phosphatase) elevation. Bone scintigraphy: hot spots in the skull. CT/MRI: bone thickening and structural deformity.
8. ScreeningHeadache and hearing loss + ALP elevation at age 50 or older are screening indicators. Determine the extent of involvement with bone scintigraphy. Confirm characteristic findings with skull X-ray and CT. Family screening (families with confirmed SQSTM1 variants).
9. DiagnosisCharacteristic X-ray findings (cotton-wool appearance, skull enlargement) + elevated serum ALP + hot spots on bone scintigraphy. Tissue biopsy is generally unnecessary. Biopsy when malignant transformation (Paget sarcoma) is suspected.
10. TreatmentBisphosphonates (zoledronic acid 5 mg single IV injection, or oral risedronate or alendronate) are standard. Goals are symptom relief and ALP normalization. NSAIDs for pain. Surgery for symptoms of nerve compression.
11. PrognosisGood symptom control with treatment. ALP normalization suppresses bone destruction. Paget sarcoma rarely develops (<1%). Hearing loss is difficult to recover. Nerve compression complications are the main cause of morbidity.
12. PreventionPrimary prevention not possible. Prophylactic bisphosphonate administration (evidence not established). Regular ALP and imaging follow-up in SQSTM1 variant families. Hearing protection.
13. ReferencesReid IR et al. Paget's disease of bone … and 9 other references

1. History

Paget disease of bone (PDB) is a disease systematically described in 1877 by the English surgeon Sir James Paget (1814–1899), who named it "osteitis deformans." Paget observed patients whose bones thickened and deformed and was the first to systematically describe the clinical features and pathological findings, emphasizing in particular the characteristic finding of gradual skull enlargement in patients with skull involvement.

However, cases similar to Paget disease existed before that. In 1726, Cotton of England described a deformed skull, and in 1769 Piquard reported a deformed skeleton. In addition, findings of Paget disease have been identified in ancient Egyptian mummies, suggesting that the disease has a history of thousands of years.

With the introduction of X-rays in the early 20th century, the characteristic imaging findings of Paget disease were identified—cotton-wool lesions in the skull, a disorganized pattern of cancellous bone, and bone thickening. In the 1960s–70s, radioisotope bone scintigraphy was introduced, making it easier to assess the extent of involvement. Calcitonin was introduced for the treatment of Paget disease in the 1970s, and from the 1980s onward bisphosphonates (etidronate, clodronate) began to be used.

In 2003, SQSTM1 (Sequestosome 1, p62) gene mutations were identified as a major cause of familial Paget disease, marking a turning point in understanding the molecular mechanism. As the genetic diversity of Paget disease was subsequently elucidated, associations with several bone metabolism genes such as RANK, OPG, and CSF1R were discovered. In 2005, phase 3 clinical trials confirmed that the intravenous bisphosphonate zoledronic acid is highly effective in inducing long-term remission of Paget disease.

In East Asia, including Korea, Paget disease is markedly rarer than in the West. This is presumed to be due to multiple factors, including genetic factors (low frequency of SQSTM1 variants), environmental factors, and differences in viral exposure. It is registered under the rare disease Special Copayment Reduction (V213), and few patients are diagnosed in Korea.

2. Causes

The cause of Paget disease, including Paget disease of the skull, is understood as a complex interaction of genetic predisposition and environmental factors. The core pathophysiology is excessive activation of osteoclasts and the resulting abnormal bone remodeling.

Genetic factors: Pathogenic variants of the SQSTM1 gene (encoding p62 protein) account for about 25–40% of familial Paget disease. The SQSTM1 protein is involved in RANK (receptor activator of NF-κB) signal transduction and the autophagy pathway, and when mutated, it causes hyperactivation and prolonged lifespan of osteoclasts. In sporadic (nonfamilial) Paget disease, the frequency of SQSTM1 variants is low, and polymorphisms of other bone metabolism genes such as TNFRSF11A (RANK), TNFRSF11B (OPG, osteoprotegerin), and CSF1R (M-CSF receptor) contribute to susceptibility.

Viral hypothesis: The viral infection hypothesis was raised from the 1970s when paramyxovirus-like (measles virus, RSV, canine distemper virus, etc.) intranuclear inclusions were observed within osteoclasts by electron microscopy. There is also experimental evidence that the measles virus nucleocapsid protein (MV-N) and matrix protein (MV-M) overactivate Paget disease osteoclasts. However, virus is often not directly detected in Paget disease, and the causal relationship between the declining prevalence of Paget disease after the introduction of measles vaccination and the role of measles virus is still debated.

Environmental factors: The regional distribution, with high prevalence of Paget disease in the United Kingdom and countries of British emigration (Australia, New Zealand, North America), suggests a role for environmental factors. In addition, the declining trend in the prevalence and severity of Paget disease in the West over recent decades is presumed to reflect environmental changes such as improved sanitation, introduction of vaccination, and dietary changes.

3. Genetics

The genetics of Paget disease are divided into familial and sporadic forms. Familial Paget disease usually shows autosomal dominant inheritance, and the risk of disease in first-degree relatives is increased about 7-fold.

The most important gene is SQSTM1 (Sequestosome 1), located at 5q35. This gene encodes the p62 protein and interacts with TRAF6 in the RANK signaling pathway to activate NF-κB. Variants in the UBA (ubiquitin-associated) domain of SQSTM1 (especially P392L, P387L, M404V) are strongly associated with Paget disease. The P392L variant is most common in people of British descent, and the lifetime risk of disease in SQSTM1 variant carriers is very high at about 80–90%. The frequency of the SQSTM1 P392L variant in Koreans is very low, which is linked to the low prevalence of Paget disease in East Asia.

Other susceptibility genes discovered through GWAS include TNFRSF11A (RANK), TNFRSF11B (OPG), TM7SF4 (DC-STAMP), CSF1R, NUP205, RIN3, OPTN, PML, and GOLGA3. All of these genes are involved in osteoclast differentiation, bone resorption, and the autophagy pathway. The autosomal dominant Paget syndromes PDB2 and PDB3 are associated with variants in RAN binding protein 2 (RANBP2/VCP) and ZNF687, respectively.

4. General epidemiology

Paget disease is the most common metabolic bone disease after osteoporosis, and its prevalence varies greatly by region and ethnicity. Isolated skull involvement accounts for a relatively small proportion of all Paget disease, but skull involvement is common in polyostotic Paget disease.

In the West, especially in the United Kingdom and countries of British emigration (Australia, New Zealand, Canada, United States), about 2–3% of people aged 55 or older are estimated to have Paget disease. There are reports that in some regions of the United Kingdom (Yorkshire, Lancashire) it reaches 7–8% of men aged 70 or older. Prevalence is intermediate in the Mediterranean, South America, and Africa, and very low in Asia (Japan, Korea, China) and in Black Africans (less than 1 per 100,000).

The sex distribution shows a male predominance (male:female about 1.5–2:1); onset is almost always after age 40, with diagnoses concentrated in the 50s–60s. Prevalence rises with age. Over the last 20–30 years the prevalence and severity of Paget disease in the West have been declining, which is presumed to reflect changes in environmental factors (reduced viral exposure, etc.). Few patients are registered for the Korean rare disease Special Copayment Reduction (V213), and accurate national epidemiological statistics are lacking.

5. Pathophysiology

The core pathogenesis of Paget disease begins with an increase in the number and excessive activation of osteoclasts, followed by repeated irregular bone remodeling cycles. Paget disease of the skull is this process occurring confined to the skull.

Osteoclast hyperactivation: Osteoclast proliferation and activation increase owing to SQSTM1 variants or abnormalities of the RANK/OPG/RANKL pathway. Osteoclasts in Paget disease have more nuclei than normal osteoclasts (25–100 vs normal 3–5) and higher activity, resorbing bone at an abnormally rapid rate. According to the paramyxovirus infection hypothesis, viral proteins may be persistently expressed in osteoclast precursors, causing osteoclast hyperactivation.

Irregular bone formation: In response to excessive bone resorption, osteoblasts are massively activated and form new bone, but this newly formed bone is woven bone in a disorganized mosaic pattern instead of normal lamellar structure. This abnormal bone has low mechanical strength and abnormally increased vascularity, causing warmth and pain.

Skull-specific findings: In the skull, Paget lesions tend to begin in the frontal and parietal bones and gradually spread to the entire skull. Initially, localized bone loss called "osteoporosis circumscripta" is observed radiographically, followed by bone thickening and cotton-wool sclerotic lesions. When the skull base is involved, bone thickening causes basilar invagination, which can lead to serious neurological complications such as compression of the lower brainstem and cerebellum, hydrocephalus, and cervical cord compression.

6. Symptoms

The clinical symptoms of Paget disease of the skull vary, and many patients are asymptomatic and discovered incidentally during blood tests or imaging.

Headache: The most common symptom; a dull persistent headache due to skull thickening and increased intracranial pressure appears. The headache is mainly frontal or occipital and sometimes worsens when bending the head or lying down.

Progressive hearing loss: Conductive or sensorineural hearing loss occurs due to Paget lesions of the bone around the inner ear (cochlea) and ossicles or compression of the skull base foramina. Hearing loss is the most common otolaryngological complication of Paget disease, and hearing is difficult to recover even after diagnosis.

Skull enlargement: A characteristic symptom is a gradual increase in hat size or head circumference due to skull thickening. Forward protrusion of the forehead or deformity of the skull contour may also occur.

Cranial nerve palsies: When the foramina of the skull base narrow due to Pagetic bone thickening, the corresponding cranial nerves are compressed. Compression of the optic canal can cause visual impairment, and compression of the internal auditory canal can cause facial nerve palsy or sensorineural hearing loss. Ptosis, diplopia, dysphagia, and voice abnormalities have rarely been reported.

Basilar invagination: When the skull base invaginates due to softening and thickening of the skull base bones, compression of the cerebellum and brainstem causes gait ataxia, limb sensory abnormalities, and lower-limb spasticity. Hydrocephalus may accompany it.

Asymptomatic discovery: Many patients with Paget disease of the skull are discovered through ALP elevation on routine blood tests without particular symptoms other than headache, or are diagnosed incidentally on skull imaging taken for other reasons.

7. Signs

The physical and laboratory signs of Paget disease of the skull are as follows.

Skull palpation: The frontal, temporal, and parietal skull may be palpated as enlarged, irregular, and hard. In some patients the skull area feels warm (reflecting increased vascularity).

Elevated serum ALP: The most characteristic laboratory finding in Paget disease is marked elevation of serum total ALP (bone-specific ALP). ALP elevation appears in Paget disease of the skull even with a single lesion, rising higher the wider the extent of involvement. ALP elevation reflects osteoblast hyperactivation and increased bone metabolism. ALP is the key indicator for monitoring treatment response and reactivation.

Skull X-ray findings: On anteroposterior and lateral skull X-rays, skull thickening, cotton-wool sclerotic lesions, and early lucent lesions (osteoporosis circumscripta) are characteristic. With basilar invagination, the odontoid process is observed rising above the skull base reference line.

CT findings: On skull CT, thickening of the inner and outer tables and the diploë of the skull, with mixed sclerotic and lucent lesions, is characteristic of Paget disease. Foraminal stenosis, basilar invagination, and brain compression can be assessed accurately.

Bone scintigraphy (99mTc-MDP): Radioisotope uptake is markedly increased at active Paget lesions. Whole-body bone scintigraphy can simultaneously assess Paget involvement of bones other than the skull, making it useful for the initial evaluation of multifocal Paget disease.

8. Screening

There is no general population screening test for Paget disease, including Paget disease of the skull. However, systematic evaluation is recommended in the following clinical situations.

When abnormal serum ALP is found: In patients aged 50 or older whose total ALP is elevated on blood tests performed for other reasons, Paget disease is included in the differential diagnosis. If liver function tests (γ-GTP, AST, ALT) are normal and bone-specific ALP is elevated, Paget disease is likely.

Headache and hearing impairment: When headache and hearing impairment progress gradually after age 50 without a particular cause, Paget disease of the skull is screened for with skull X-ray and ALP testing.

Family screening: In first-degree relatives (parents, siblings, children) of Paget disease patients carrying SQSTM1 variants, SQSTM1 genotype analysis and periodic (every 3–5 years) measurement of serum ALP are recommended.

Imaging screening: When suspected, cotton-wool lesions are confirmed by skull X-ray, and abnormal findings are evaluated in detail by CT. The extent of involvement of multifocal Paget disease is determined early with whole-body bone scintigraphy.

9. Diagnosis

The diagnosis of Paget disease of the skull is made by a combination of characteristic imaging findings and elevated serum ALP. In most cases, tissue biopsy is unnecessary.

Diagnostic criteria: ① characteristic findings of Paget disease on skull X-ray or CT (cotton-wool sclerosis, skull thickening, mixed sclerotic-lucent lesions), ② elevated serum total ALP (especially bone-specific ALP), ③ hot spots in the skull on bone scintigraphy. Paget disease is diagnosed when two or more of these three are met.

Differential diagnosis: Exclude skull osteomyelitis (including Pott's disease; elevated temperature, elevated ESR, soft tissue swelling), skull metastatic cancer (identification of the primary malignancy needed, FDG-PET), fibrous dysplasia (onset in childhood–adolescence, GsNα gene variants), skull sarcoma (rapid increase in size, worsening pain, sharp rise in ALP), and multiple myeloma (serum and urine M protein, bone marrow examination).

Caution regarding Paget sarcoma: When pain suddenly worsens at an existing Paget site, ALP rises sharply, and a soft tissue mass forms, Paget sarcoma (malignant transformation to osteosarcoma or fibrosarcoma) is suspected. The incidence is less than 1% of all Paget patients, but the prognosis is very poor. In this case CT/MRI and biopsy are needed.

10. Treatment

The standard treatment for Paget disease of the skull is bisphosphonates, aiming at normalization of bone metabolism and symptom relief.

Zoledronic acid (zoledronate): The most effective of the intravenous bisphosphonates. A single 5 mg IV infusion achieves long-term (at least 2–6 years) ALP normalization and symptom relief in Paget disease. In the HORIZON phase 3 trial, zoledronic acid showed a superior ALP normalization rate compared with risedronate (89% vs 58%). Adequate calcium (1,000–1,200 mg/day) and vitamin D (800 IU/day or more) supplementation before administration is needed to prevent renal impairment. Re-administration is possible upon relapse.

Oral bisphosphonates: Risedronate (30 mg/day for 2 months) or alendronate (40 mg/day for 6 months) are also effective. Response rates are lower than with zoledronic acid, but they are alternatives when IV access is difficult or adverse effects are a concern. They must be taken in the morning on an empty stomach with 200 mL of water, and an upright upper-body posture must be maintained for at least 30 minutes (to prevent esophageal irritation).

Symptomatic treatment: NSAIDs or acetaminophen are used for headache and bone pain. For hearing loss, hearing assistive devices (hearing aids, etc.) are helpful. Hearing is rarely restored with bisphosphonate treatment.

Surgery: When there is cervical cord compression due to basilar invagination, hydrocephalus, or severe cranial nerve palsy, neurosurgical intervention (suboccipital decompression, lateral ventricular shunt) may be needed. Stabilizing bone metabolism with bisphosphonate treatment before surgery is recommended.

11. Prognosis

The prognosis of Paget disease of the skull varies with the timing of diagnosis, extent of involvement, and presence of complications. When bone metabolism is normalized with bisphosphonates, most symptoms can be controlled, but hearing loss or nerve damage that has already occurred is often irreversible.

Treatment response: When serum ALP normalizes after a single dose of zoledronic acid, remission is often maintained for 2–6 years or more. ALP normalization is an important indicator of suppression of bone destruction. Headache often improves after treatment, but skull deformity or skull enlargement itself cannot be reversed.

Hearing prognosis: Bisphosphonate treatment can prevent further worsening of Paget-associated hearing loss, but recovery of hearing loss that has already occurred is difficult. Early diagnosis and early treatment are important for preserving hearing.

Paget sarcoma: It occurs in less than 1% of all Paget patients but has a very poor prognosis (5-year survival <5%). Paget sarcoma of the skull presents as osteosarcoma, fibrosarcoma, chondrosarcoma, and so on. Whether bisphosphonate treatment prevents malignant transformation has not yet been established.

Long-term prognosis: The life expectancy of Paget disease patients overall is reported to be similar to that of the general population. The main causes of morbidity are hearing loss, neurological complications, and rarely Paget sarcoma. The goal of treatment is to minimize the occurrence of these complications with bisphosphonate treatment.

12. Prevention

There is currently no established method of primary prevention for Paget disease. Genetic counseling and regular follow-up in families carrying SQSTM1 variants are key to early diagnosis.

Genetic testing is recommended in first-degree relatives (parents, children, siblings) of patients with confirmed SQSTM1 variants, with monitoring of serum ALP and bone-specific ALP every 3–5 years in variant-positive individuals. When ALP elevation is detected early, bisphosphonate treatment can be started after imaging confirmation, regardless of symptoms, to prevent complications. To protect hearing, avoidance of noisy environments, caution with ototoxic drugs, and regular hearing tests are recommended. In patients receiving bisphosphonates, sharing information before dental procedures and oral hygiene management are important for preventing osteonecrosis of the jaw (ONJ).

13. References

  1. Reid IR, Bolland MJ, Grey A, et al. Effects of zoledronate on cancer, cardiac events, and mortality in osteoporotic women. J Bone Miner Res. 2010;25(5):1235-1241. PMID: 19874189.
  2. Ralston SH, Langston AL, Reid IR. Pathogenesis and management of Paget's disease of bone. Lancet. 2008;372(9633):155-163. DOI: 10.1016/S0140-6736(08)61035-1. PMID: 18620951.
  3. Michou L, Brown JP. Genetics of bone diseases: Paget's disease, fibrous dysplasia, osteopetrosis, and osteogenesis imperfecta. Joint Bone Spine. 2011;78(3):252-258. DOI: 10.1016/j.jbspin.2010.07.010. PMID: 20843731.
  4. Singer FR, Bone HG, Hosking DJ, et al. Paget's disease of bone: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(12):4408-4422. DOI: 10.1210/jc.2014-2910. PMID: 25406789.
  5. Reid IR, Miller P, Lyles K, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med. 2005;353(9):898-908. DOI: 10.1056/NEJMoa044241. PMID: 16135834.
  6. Whyte MP. Paget's disease of bone. N Engl J Med. 2006;355(6):593-600. DOI: 10.1056/NEJMcp060066. PMID: 16899778.
  7. Takata S, Yasui N, Nakatsuka K, Ralston SH. Evolution of understanding of genetics of Paget's disease of bone and related diseases. J Bone Miner Metab. 2004;22(6):519-523. DOI: 10.1007/s00774-004-0515-6. PMID: 15490264.
  8. Langston AL, Campbell MK, Fraser WD, et al. Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget's disease of bone. J Bone Miner Res. 2010;25(1):20-31. DOI: 10.1359/jbmr.090709. PMID: 19580465.
  9. Chung PY, Beyens G, Riches PL, et al. Genetic variation in the TNFRSF11A gene encoding RANK is associated with susceptibility to Paget's disease of bone. J Bone Miner Res. 2010;25(12):2633-2644. DOI: 10.1002/jbmr.163. PMID: 20593424.
  10. Park IH, Yoo SE, Lee JC, et al. A rare case of Paget's disease of bone in a Korean patient. J Korean Orthop Assoc. 2018;53(4):370-375. DOI: 10.4055/jkoa.2018.53.4.370.